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 Abstract
Aim: to find out the relationship, if any, between the extent of the overall genomic DNA methylation, and clinical and 
pathological features of the sporadic endometrial adenocarcinomas in women.
Material: genomic DNA was isolated from 44 primary uterine cancer tissue specimens. There were eight G
1
, 24 
G
2
 and twelve G
3
 tumors.
Methods: m5dC level was estimated after enzymatic digestion of DNA into nucleotides, 32P-postlabelling, two-
dimensional thin-layer chromatography on cellulose plates and phosphorobioimaging. The overall m5dC of the 
uterine cancer DNAs expressed as a ratio: (pm5dC/pm5dC+pdC) x 100% was compared to results obtained for 
parallel investigated but published earlier normal human endometrium DNAs.
Results: mean total cancer DNA methylation (3.48±0.46%) was significantly higher than that of the normal 
proliferative endometrium (2.94±0,4%, p=0.003) and lower than that of the secretory endometrium DNAs 
(3.75±0,47%, p=0.03). Among all endometrial cancer DNAs six were found to be hypomethylated, eight were 
hypermethylated, whereas the remaining 30 had m5dC within range of normal endometrium. Total DNA methylation 
was significantly higher in poorly differentiated (G
3
) than in lower grade neoplasms (3.94±0.46 vs. 3.3 ±0.32 %, 
p=0.025). Lower levels of DNA methylation seemed to be associated with diminished tumor invasiveness. 
Conclusions: our results suggest that alterations in overall DNA methylation seem to be a result of neoplastic 
transformation and could therefore be used as a prognostic molecular marker of endometrial cancer. 
 Key words: adenocarcinoma / DNA methylation / 
        / molecular epidemiology / 
Otrzymano: 30.08.2009
Zaakceptowano do druku: 15.10.2009
Adres do korespondencji:
Krzysztof Postawski
II Department of Gynecology, Medical University of Lublin, 
20-954 Lublin, Poland
ul. Jaczewskiego 8, 
tel. 81 7244628 
e-mail: postawski@yahoo.com 
©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e 825
P R A C E  O R Y G I N A L N E
  g in eko l og ia 
Postawski K, et al.
Ginekol Pol. 2009, 80, 824-827 
Introduction
	 DNA	 methylation	 is	 an	 enzymatic,	 epigenetic	
modification,	which	is	restricted	to	cytosine	residues	at	carbon-5	
of	the	pyrimidine	ring	[1].	Recent	evidences	implicate	the	DNA	
methylation	 in	 the	 regulation	 of	 gene	 expression,	 in	 genomic	
imprinting,	 in	 inherited	 diseases	 (e.g.	 fragile-X	 syndrome),	 in	
distinguishing	host	DNA	from	foreign	DNA,	and	in	oncogenesis	
[2,	3].	
	 Alterations	 in	 DNA	 methylation	 are	 among	 the	 most	
common	 and	 earliest	 events	 associated	 with	 neoplasia	 [1].	 It	
has	 been	 generally	 accepted	 that	 total	 5-methyldeoxycytosine	
content	is	decreased	in	most	human	cancers	[4].	Genomic	DNA	
demethylation	is	involved	in	increased	mutation	rate,	in	increased	
expression	of	oncogenes,	and	finally	in	tumorigenesis.	Counts	and	
Goodman	have	suggested	that	only	moderate	demethylation	plays	
a	critical	role	in	carcinogenesis	and	that	excessive	hypomethylation	
could	destroy	the	malignant	cells	[5].	Gama-Sosa	et	al.	showed	
that	53%	of	primary	malignancies	exhibited	lower	m5dC	content	
as	 compared	with	 normal	 tissues	 and	 benign	 tumors	 [6].	They	
also	noted	 large	differences	 in	overall	DNA	methylation	 in	 the	
same	 histological	 type	 of	 neoplasm,	 potentially	 due	 to	 grade	
of	 the	 tumor	or	 contamination	of	 the	 investigated	 sample	with	
the	 normal	 cells.	 Bernardino	 et	 al.	 believe	 that	 variations	 of	
hypomethylation,	which	 is	 a	 consistent	 characteristic	 of	 breast	
cancer,	may	not	correlate	with	tumor	progression	[7].	
	 However,	Soares	et	al.	found	that	 in	such	cancer	there	is	
a	 statistically	 significant	 correlation	 between	 the	 global	 DNA	
methylation	 and	 the	 disease	 stage,	 tumor	 size	 and	 histological	
grade	of	malignant	neoplasms	[8].	
	 They	 also	 revealed	 that	 highest	 demethylation	 of	 DNA	
was	present	in	G
2
	tumors.	Shen	et	al.	discovered	that	total	DNA	
demethylation	 level	 is	 closely	 correlated	 with	 the	 biological	
characteristic	of	liver	cancer	being	more	significant	in	cases	with	
tumor	infiltration	and	metastasis	[9].	
	 Moreover,	 the	 degree	 of	 reduced	DNA	methylation	was	
related	to	late	histopathological	hepatocellular	carcinoma	(HCC)	
grade	 and	 large	 tumor	 size	 in	 Lin	 et	 al.	 investigations.	 These	
authors	also	suggest	that	genome-wide	hypomethylation	in	HCC	
is	the	continuing	process	that	persists	throughout	the	lifetime	of	
the	tumor	cells	rather	than	a	historical	event	occurring	at	the	onset	
of	cancerous	growth	[10].	Bedford	and	van	Helden	did	not	reveal	
any	 change	 of	 overall	DNA	methylation	 in	 a	 case	 of	 prostatic	
cancers	spreading	by	metastasis	[11].
	 Popiela	 et	 al.	 discovered	 that	 endometrial	 cancers	 in	
women	 contain	 higher	 grade	 of	 total	 DNA	 methylation	 level	
than	 those	 estimated	 in	 normal	 or	 preneoplastic	 endometrium	
[12].	Higher	mean	DNA	methylation	 level	 than	 those	 revealed	
in	normal	 tissue	was	also	noted	by	Kliasheva	et	al.	 in	cases	of	
human	gastric	cancers	or	lung	cancer	in	men	[13,	14].
	 An	assessment	of	the	methylation	level	within	neoplastic	
tissues	may	provide	the	basis	for	future	advances	in	surgical	and	
pharmacologic	treatment	of	human	malignant	diseases.	Staging	
of	 cancers	 on	 the	 levels	 of	 DNA	 methylation	 will	 provide	 a	
convenient	way	to	assess	a	tumor’s	biologic	aggressiveness	and	
to	predict	patient	outcome	[15].	
	 Therefore,	 the	 aim	 of	 our	 study	 was	 to	 find	 out	 the	
relationship,	 if	 any,	 between	 the	 extent	 of	 the	 overall	 genomic	
DNA	methylation,	and	clinical	and	pathological	features	of	 the	
sporadic	endometrial	adenocarcinomas	in	women.
Materials and Methods
	 Uterine	carcinoma	samples	were	obtained	from	44	women	
(age	range	34-81),	who	underwent	surgical	procedures	at	the	II	
Department	of	Gynecology	of	the	Medical	University	of	Lublin,	
Poland.	As	a	control,	normal	endometrial	samples	obtained	from	
25	 regularly	 cycling,	 fertile	 women	 were	 used	 which	 results	
concerning	 total	DNA	methylation	were	published	earlier	 [16].	
None	of	the	women	received	any	therapy	prior	to	surgery.	
 Streszczenie
Cel pracy: poszukiwanie zależności między poziomem globalnej metylacji DNA, a niektórymi histologicznymi i 
klinicznymi cechami gruczolakoraków błony śluzowej macicy u kobiet.
Materiał i metody: odsetek 5-metylocytozyny (m5dC) zbadano przy zastosowaniu metody 32P-postlabeling oraz 
dwukierunkowej chromatografii cienkowarstwowej (TLC 2-D) z kwantyfikacją radioaktywności nukleozasad przy za-
stosowaniu czytnika BAS 2000 w próbkach wysokooczyszczonych preparatów genomowego DNA wyizolowanego 
z 44 guzów (ośmiu w stopniu G
1
, 24 G
2
 i dwunastu G
3
). Wyliczony według wzoru: [(m5dC/ m5dC+dC) x 100] poziom 
zmodyfikowanej zasady korelowano z wiekiem chorych, odróżnicowaniem mikroskopowym guza oraz głębokoś-
cią naciekania błony mięśniowej ścian macicy przez nowotwór. Poziom globalnej metylacji DNA w nowotworach 
przeanalizowano ponadto w relacji do uzyskanych równolegle, ale już opublikowanych, wyników badań stopnia 
metylacji w prawidłowym endometrium.
Wyniki: średni poziom globalnej metylacji DNA w gruczolakorakach endometrium (3,48±0,46%) był wyższy niż 
zanotowano we wzrostowej (p= 0,003) i niższy niż stwierdzono w wydzielniczej błonie śluzowej macicy (p=0,03). 
Hipometylację stwierdzono w 6, podczas gdy hipermetylacja genomowego DNA wystąpiła w ośmiu nowotwo-
rach. Średnia, globalna metylacja guzów w stopniu G
3
 była wyższa niż odnotowano w pozostałych (3,94±0,46 vs 
3,3±0.32 %, p=0,025). Stwierdzono narastanie poziomu zmodyfikowanego DNA w relacji do stopnia naciekania 
ścian macicy przez nowotwór.
Wnioski: uzyskane wyniki wskazują, że zmiany metylacji cytozyny mogą być raczej skutkiem stopnia transformacji 
nowotworowej endometrium u kobiet, a nie przyczyną wystąpienia gruczolakoraka.
 Słowa kluczowe: gruczolakorak / metylacja DNA / 
                  / epidemiologia molekularna / 
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	 Tissues	 were	 collected	 in	 the	 operating	 theater	 under	 a	
dissecting	microscope	by	a	punch	biopsy	of	 the	clearly	visible	
uterine	malignancy	 after	 dissection	 of	 the	 excised	 uterus.	 The	
tissue	 samples	were	 immediately	 frozen	 in	 liquid	nitrogen	 and	
stored	at	-80ºC	until	DNA	extraction	was	performed.	Each	tissue	
specimen	was	evaluated	at	the	Department	of	Pathology.	Cancer	
tissues	 were	 classified	 according	 to	 the	WHO	 staging	 system	
[17].	The	Ethical	Committee	of	the	Medical	University	of	Lublin	
approved	the	study,	and	an	informed	written	consent	was	obtained	
from	each	woman.	All	DNA	investigations	were	accomplished	at	
the	 Institute	 de	Biologie	Moléculaire	 et	Cellulaire,	 Strasbourg,	
France.
	 DNA	 extraction	 from	 tissue	 samples	 and	 estimation	 of	
m5dC	level	after	enzymatic	digestion	of	DNA	into	nucleotides,	
32P-postlabelling,	two-dimensional	thin	layer	chromatography	on	
cellulose	plates	was	performed	as	described	earlier	[16,	18].	
The	radioactivity	of	the	labeled	spots	containing	[32P]	pm5dC	and	
[32P]	 pdC	was	measured	 by	 bio-imaging	 analyzer	 (BAS	 2000,	
Fuji).	 The	 pm5dC	 content	 was	 expressed	 as	 a	 ratio:	 (pm5dC/
pm5dC+pdC)	x	100%.	Each	value	was	calculated	from	counting	
of	 two	 separate	 DNA	 preparations	 of	 each	 individual	 tissue	
specimen.	
	 Statistical	 analysis	 was	 performed	 using	 the	 Statistica	 8	
package.	Descriptive	statistics	were	summarized	by	calculating	
mean	 values,	 standard	 deviations	 and	 ranges.	 The	 comparison	
of	m5dC	 content	 between	 tissues	 groups	was	 based	 on	 a	 non-
parametric	Mann-Whitney	U	test	or	Wald-Wolfowitz	Runs	test,	
when	 appropriate.	A	 p	 value	 less	 than	 0.05	was	 considered	 as	
significant.
Results
	 We	 have	 previously	 demonstrated	 that	 the	 overall	 DNA	
methylation	in	the	normal	human	endometrium	depends	on	the	
menstrual	cycle	phase	[16].	DNA	methylation	was	significantly	
lower	 in	 the	 proliferative	 than	 in	 the	 secretory	 endometrium	
samples.	Therefore,	we	have	compared	the	results	of	DNA	m5dC	
content	 in	 neoplastic	 tissues	 to	 DNA	 methylation	 in	 normal	
proliferative	and	secretory	endometrium	separately.	
	 The	overall	content	m5dC	in	the	uterine	cancer	DNA	was	
3.48%±0.46	%.	
	 As	compared	to	the	normal	endometrium,	this	value	was	
significantly	 higher	 than	 the	 total	 m5dC	 in	 the	 proliferative	
endometrium	 (p=0.003),	 but	 it	 was	 significantly	 lower	 than	 in	
DNA	from	the	secretory	endometrium	(p=0.03).
	 The	 individual	 uterine	 cancer	 DNAs	 were	 considered	
hypomethylated	 if	 the	 m5dC	 values	 were	 below	 the	 mean	
for	 normal	 proliferative	 endometrium	 (2.94%±0.40%),	 or	
hypermethylated	when	the	percentage	of	the	m5dC	was	above	the	
mean	value	of	the	secretory	endometrium	(3.75%±0.47%).
	 There	 were	 six	 (14%)	 hypomethylated	 and	 eight	 (18%)	
hypermethylated	uterine	cancer	samples.	The	levels	of	m5dC	in	
the	remaining	30	(68%)	neoplasms	were	within	the	range	of	the	
normal	proliferative	and	secretory	endometrium	specimens.
Within	 neoplasms	 exhibiting	 m5dC	 level	 in	 the	 range	 of	 the	
normal	endometrium	samples	the	most	frequent	were	G
2
	tumors	
(50%),	whereas	the	percentages	of	G
1
	and	G
3
	tumors	were	nearly	
the	 same	 (27%	 vs.	 23%,	 respectively).	 The	 percentage	 of	 G
2
 
uterine	cancers	was	not	changed	in	hypomethylated	neoplasms,	
while	the	percentage	of	G
1
	declined	to	17%	and	the	percentage	of	
G
3
	 adenocarcinomas	 increased	 to	33%.	Hypermethylated	DNA	
was	present	only	in	G
3
	(75%)	and	G
2
	(25%)	tumors.
	 In	 all	 uterine	 cancers	 investigated	 the	 overall	 DNA	
methylation	 of	 lower	 histological	 grade	 neoplasms	 (G
1
	 and	
G
2
)	was	significantly	lower	than	that	of	G
3
	tumors	(3.3±0.3	vs.	
3.94±0.46	%,	p<0.05).	(Figure	1).	
	 Most	of	the	G
1
	and	G
2
	neoplasms	(66%)	displaying	lower	
values	of	methylated	DNA	did	not	invade	or	infiltrate	the	uterine	
wall	more	than	one	half	of	its	thickness.	In	contrast,	the	neoplasms	
with	 hypermethylated	 DNA	 were	 all	 associated	 with	 deep	
myometrial	 invasion,	whereas	 in	 hypomethylated	 group	 it	was	
observed	only	in	50%	cases	(3	neoplasms).	In	cancers	confined	
only	to	endometrial	mucosa	(n=4)	mean	5-methyldeoxycytosine	
content	was	lower	than	was	estimated	in	tumors	invading	more	
 
Figure 1. Mean overall m5dC in less dedifferentiated (G1 and G2) and G3 sporadic 
adenocarcinomas in women (* - p<0.05).
 
Figure 2. Mean total m5dC content in endometrial adenocarcinomas according to 
infiltration of myometrium: NI - cancer confined to endometrial mucosa,  
<1/2- infiltration less than one half of uterine wall, >1/2- infiltration more than one half 
of uterine wall thickness. 
*- p<0.05; **- p<0.04 (Wald-Wolfowitz Runs test).
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than	one	half	of	uterine	wall	thickness	(3.29±0.33	vs.	3.62±0.55%,	
p<0,05).	Higher	mean	of	m5dC	level	in	such	cancers	in	relation	
to	 adenocarcinomas	 displaying	 lower	 myometrial	 infiltration	
(3.33±0.29%)	was	recognized	only	by	applying	Wald-Wolfowitz	
runs	test	(p<0.04).	(Figure	2).
Discussion
	 Our	 investigations	 in	 a	 sporadic	 endometrial	 carcinomas	
demonstrated	that	the	mean	global	DNA	methylation	was	in	the	
range	of	normal	endometrium.	Only	six	uterine	cancers	exhibited	
hypomethylation	of	their	DNAs	compared	to	the	range	of	normal	
endometrium.	 Additionally,	 there	 were	 no	 values	 lower	 than	
2.2%,	which	was	recognized	as	the	lowest	value	in	a	DNA	sample	
of	normal	proliferative	endometrium.	These	results	indicate	that	
excessive	demethylation	of	the	genome	which	would	be	expected	
to	 inhibit	 tumorigenesis,	 does	 not	 take	 place	 in	 human	 uterine	
cancer	 [19].	Alternatively,	 the	 data	 suggest	 that	 in	 endometrial	
carcinoma	 hypermethylation	 of	 the	 genome	 is	 more	 common	
event	than	demethylation.	Moreover,	hypermethylation	of	DNA,	
which	 was	 not	 observed	 in	 the	 well-differentiated	 tumors	 but	
was	 mainly	 attributed	 to	 poorly-differentiated	 neoplasms	 and	
some	G
2
	cancers,	may	be	a	molecular	marker	of	high-risk	lesions	
exhibiting	 the	 highest	 rates	 of	 solid	 growth.	However,	 in	 such	
tumors	we	also	observed	both	hypomethylation	as	well	as	normal	
values	of	DNA	m5dC.	
	 According	to	presented	results,	it	seems	that	normal	or	low	
DNA	methylation	 status	 could	 indicate	 a	 low	 risk	 endometrial	
carcinoma,	 because	 75%	 of	 the	 tumors	 exhibiting	 normal	 or	
decreased	values	of	methylated	DNA	were	G
1
	or	G
2
	neoplasms	
which	are	believed	as	less	aggressive	tumors	[20].	
	 Our	 results	 could	 also	 clearly	 indicate	 that	 lower	 total	
DNA	 methylation	 is	 associated	 with	 diminished	 myometrial	
invasiveness	 of	 the	 uterine	 cancer	 which	 was	 recognized	 as	 a	
good	prognostic	factor	of	the	disease	[20].	
	 The	extent	of	DNA	methylation	in	endometrial	cancer	was	
significantly	higher	in	G
3
	than	in	G
2	
and	G
1
	neoplasms	containing	
>50%,	 6%-50%	 and	 <5%	 of	 undifferentiated,	 solid	 neoplastic	
cells,	 respectively	 [16].	These	data	 support	 the	 conclusion	 that	
changes	in	the	global	level	of	methylated	cytosine	are	related	to	
the	quantity	 of	 nonsquamous	 solid	 growth.	 Indeed,	 about	 90%	
of	the	G
3
	uterine	cancers	had	DNA	m5dC	levels	higher	than	the	
mean	content	of	m5dC	in	lower	histological	grade	tumors.	
	 Although	 local	 changes	 in	 DNA	 methylation	 precede	
malignancy,	our	 results	 indicate	 that	 the	global	changes	appear	
to	be	dependent	on	the	histological	grade	or	invasiveness	of	the	
endometrial	 neoplasms	 [21].	Thus,	 it	 appears	 that	 increases	 in	
global	DNA	methylation	are	a	result	of	neoplastic	transformation.	
This	conclusion	can	be	supported	by	fact,	that	in	our	investigations	
the	overall	DNA	methylation	in	human	uterine	sporadic	cancers	
was	 not	 related	 to	 the	 age	 of	 the	 affected	 women.	 This	 is	 in	
contrast	 to	 the	 regional	 changes	 of	m5dC	 content	 in	 colorectal	
cancer	tissue,	in	which	aging	appears	to	be	a	major	contributing	
factor	to	DNA	hypermethylation,	but	of	certain	gene	loci	[22].
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